Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer.  See definition of “accelerated filer and large accelerated filer” in Rule 12b-2.

 

Large accelerated filer     |_|                                                  Accelerated filer      |X|                                      Non-accelerated filer      |_|

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  |_|  No  |X|

 

 

---

 

 

As of February 8, 2008, 15,597,768 shares of the Registrant’s common stock, par value $0.01 per share (“Common Stock”), were outstanding.

 

 

 

---

 

 

TABLE OF CONTENTS

Page

 

 

PART I

FINANCIAL INFORMATION

1

 

Item 1

Financial Statements

1

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3	Quantitative and Qualitative Disclosures about Market Risk	30

Item 4

Controls and Procedures

30

 

PART II

OTHER INFORMATION

31

 

Item 1

Legal Proceedings

31

Item 1A	Risk Factors	31
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	32

Item 3

Defaults Upon Senior Securities

33

Item 4

Submission of Matters to a Vote of Security Holders

33

Item 5

Other Information

33

Item 6

Exhibits

34

 

 

 

-i-

---

 

PART I.                      FINANCIAL INFORMATION

 

Item 1.

Financial Statements.

 

IMMTECH PHARMACEUTICALS, INC. AND SUBSIDIARIES
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
		December 31,				March 31,
ASSETS		2007				2007
CURRENT ASSETS:
Cash and cash equivalents		$	9,444,196			$	12,461,795
Restricted funds on deposit			4,962,342				3,118,766
Other current assets			487,860				98,627
Total current assets			14,894,398				15,679,188
PROPERTY AND EQUIPMENT - Net			92,241				140,263
PREPAID RENT			3,253,045				3,309,240
OTHER ASSETS			477,279				15,477
TOTAL		$	18,716,963			$	19,144,168
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable		$	2,842,657			$	2,585,395
Accrued expenses			1,005,456				375,925
Deferred revenue			5,314,142				1,726,673
Total current liabilities			9,162,255				4,687,993
DEFERRED REVENUE—NON CURRENT			3,694,400
Total liabilities			12,856,655				4,687,993
STOCKHOLDERS' EQUITY:
Preferred stock, par value $0.01 per share, 3,913,000 shares authorized and
unissued as of December 31, 2007 and March 31, 2007.
Series A convertible preferred stock, par value $0.01 per share, stated value

 

 

 

-1-

---

 

 

$25 per share, 320,000 shares authorized, 54,500 and 55,500 shares issued
and outstanding as of December 31, 2007 and March 31, 2007, respectively;
aggregate liquidation preference of $1,379,435 as of December 31, 2007.			1,379,435				1,425,283
Series B convertible preferred stock, par value $0.01 per share, stated value
$25 per share, 240,000 shares authorized, 11,464 and 13,464 shares issued
and outstanding as of December 31, 2007 and March 31, 2007, respectively;
aggregate liquidation preference of $291,126 as of December 31, 2007.			291,126				348,621
Series C convertible preferred stock, par value $0.01 per share, stated value
$25 per share, 160,000 shares authorized, 45,536 shares issued and outstanding
as of December 31, 2007 and March 31, 2007; aggregate liquidation preference
of $1,157,889 as of December 31, 2007.			1,157,889				1,180,345
Series D convertible preferred stock, par value $0.01 per share, stated value
$25 per share, 200,000 shares authorized, 115,200 and 117,200 shares issued
and outstanding as of December 31, 2007 and March 31, 2007 respectively;
aggregate liquidation preference of $2,916,925 as of December 31, 2007.			2,916,925				3,010,914
Series E convertible preferred stock, par value $0.01 per share, stated value
$25 per share, 167,000 shares authorized, 98,600 and 110,200 shares issued
and outstanding as of December 31, 2007 and March 31, 2007, respectively;
aggregate liquidation preference of $2,496,639 as of December 31, 2007.			2,496,639				2,831,116
Common stock, par value $0.01 per share, 100,000,000 shares
authorized, 15,574,685 and 15,333,221 shares issued and outstanding
as of December 31, 2007 and March 31, 2007, respectively			155,747				153,332
Additional paid-in capital			109,589,482				106,031,851
Deficit accumulated during the developmental stage			(112,126,935	)			(100,525,287	)
Total stockholders' equity			5,860,308				14,456,175
TOTAL		$	18,716,963			$	19,144,168
See notes to condensed consolidated financial statements (unaudited).

 

-2-

---

 

 

IMMTECH PHARMACEUTICALS, INC. AND SUBSIDIARIES

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

																		October 15,
																		1984
		Three Months Ended								Nine Months Ended								(Inception) to
		December 31,								December 31,								December 31,
		2007				2006				2007				2006				2007
REVENUES		$	1,835,399			$	546,170			$	3,692,081			$	2,979,109			$	28,774,834
EXPENSES:
Research and development			4,213,952				1,862,304				8,414,603				6,086,466				68,528,536
General and administrative			2,926,309				2,629,592				6,857,515				7,213,243				70,834,872
Other (litigation settlement)															(1,874,454	)			(1,874,454	)
Equity in loss of joint venture																			135,002
Total expenses			7,140,261				4,491,896				15,272,118				11,425,255				137,623,956
LOSS FROM OPERATIONS			(5,304,862	)			(3,945,726	)			(11,580,037	)			(8,446,146	)			(108,849,122	)
OTHER INCOME (EXPENSE):
Interest income			100,992				117,046				380,997				399,741				1,855,028
Interest expense																			(1,129,502	)
Loss on sales of investment securities - net																			(2,942	)
Cancelled offering costs																			(584,707	)
Gain on extinguishment of debt																			1,427,765
Other income			100,992				117,046				380,997				399,741				1,565,642

 

 

 

-3-

---

 

 

NET LOSS			(5,203,870	)			(3,828,680	)			(11,199,040	)			(8,046,405	)			(107,283,480	)
CONVERTIBLE PREFERRED STOCK DIVIDENDS AND CONVERTIBLE PREFERRED STOCK PREMIUM DEEMED DIVIDENDS			(132,629	)			(136,934	)			(402,608	)			(416,824	)			(7,213,354	)
REDEEMABLE PREFERRED STOCK CONVERSION, PREMIUM AMORTIZATION AND DIVIDENDS																			2,369,899
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		$	(5,336,499	)		$	(3,965,614	)		$	(11,601,648	)		$	(8,463,229	)		$	(112,126,935	)
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS:
Net loss		$	(0.33	)		$	(0.27	)		$	(0.73	)		$	(0.57	)
Convertible preferred stock dividends and convertible preferred stock premium deemed dividends			(0.01	)			(0.01	)			(0.02	)			(0.03	)
BASIC AND DILUTED LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS		$	(0.34	)		$	(0.28	)		$	(0.75	)		$	(0.60	)
WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER SHARE			15,534,138				14,108,835				15,438,240				14,040,801
See notes to condensed consolidated financial statements (unaudited).

 

 

-4-

---

IMMTECH PHARMACEUTICALS, INC. AND SUBSIDIARIES
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

																		October 15,
																		1984
		Three Months Ended								Nine Months Ended								(Inception) to
		December 31,								December 31,								December 31,
		2007				2006				2007				2006				2007
OPERATING ACTIVITIES:
Net loss		$	(5,203,870	)		$	(3,828,680	)		$	(11,199,040	)		$	(8,046,405	)		$	(107,283,480	)
Adjustments to reconcile net loss to net cash used in
operating activities:
Compensation recorded related to issuance of common stock,
common stock options and warrants			724,611				1,137,595				2,118,562				2,370,982				32,811,533
Depreciation and amortization of property and equipment			35,571				37,861				109,071				115,074				1,297,764
(Gain)/Loss on disposal of fixed assets																			5,982
Equity in loss of joint venture																			135,002
Loss on sales of investment securities - net																			2,942
Amortization of debt discounts and issuance costs																			134,503
Gain on extinguishment of debt																			(1,427,765	)
Changes in assets and liabilities:
Other current assets			(88,788	)			1,796,200				(389,233	)			(186,761	)			(487,860	)
Other assets			(165,750	)							(461,802	)			70,399				(477,279	)
Accounts payable			1,415,919				(312,729	)			257,262				(645,650	)			3,170,192
Accrued expenses			753,378				124,513				629,531				150,277				1,668,469
Deferred revenue			6,217,499				(546,171	)			7,281,869				2,669,797				9,008,542
Net cash provided by (used in) operating activities			3,688,570				(1,591,411	)			(1,653,780	)			(3,502,287	)			(61,441,455	)
INVESTING ACTIVITIES:
Purchase of property and equipment			(4,854	)			(1,732	)			(4,854	)			(41,403	)			(1,622,103	)
Restricted funds on deposit			(4,268,611	)			693,038				(1,843,576	)			(2,986,319	)			(4,962,342	)

 

 

-5-

---

 

 

Advances to joint venture					(135,002)
Proceeds from maturities of investment securities					1,800,527
Purchases of investment securities	-	-	-	-	(1,803,469)
Net cash provided by (used in) investing activities	(4,273,465)	691,306	(1,848,430)	(3,027,722)	(6,722,389)
FINANCING ACTIVITIES:
Advances from stockholders and affiliates					985,172
Proceeds from issuance of notes payable					2,645,194
Principal payments on notes payable					(218,119)
Payments for debt issuance costs					(53,669)
Payments for extinguishment of debt					(203,450)
Net proceeds from issuance of redeemable preferred stock					3,330,000
Net proceeds from issuance of convertible preferred stock and warrants					17,085,434
Payments of convertible preferred stock dividends and for fractional shares of common stock resulting from the conversions of convertible preferred stock	(513)	(368)	(979)	(775)	(6,571)
Net proceeds from issuance of common stock	189,679		485,590	29,994	53,798,490
Additional capital contributed by stockholders	-	-	-	-	245,559
Net cash provided by (used in) financing activities	189,166	(368)	484,611	29,219	77,608,040
NET  INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(395,729)	(900,473)	(3,017,599)	(6,500,790)	9,444,196
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	9,839,925	8,537,550	12,461,795	14,137,867	-
CASH AND CASH EQUIVALENTS, END OF  PERIOD	$      9,444,196	$    7,637,077	$      9,444,196	$     7,637,077	$         9,444,196
See notes to condensed consolidated financial statements (unaudited).

 

 

 

-6-

---

 

IMMTECH PHARMACEUTICALS, INC. AND SUBSIDIARIES

(A DEVELOPMENT STAGE ENTERPRISE)

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

---

 

1.	BASIS OF PRESENTATION

 

The accompanying condensed consolidated financial statements have been prepared by Immtech Pharmaceuticals, Inc. and its subsidiaries (the “Company”) pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, in the opinion of management, include all adjustments necessary for a fair statement of results for each period shown (unless otherwise noted herein, all adjustments are of a normal recurring nature).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such SEC rules and regulations.  The Company, with a fiscal year ending March 31, believes that the disclosures made are adequate to prevent the financial information given from being misleading.  It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K.

 

2.	COMPANY BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Description of Business – Immtech Pharmaceuticals, Inc. (a development stage enterprise) and its subsidiaries, is a pharmaceutical company working to commercialize drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders.  Immtech has advanced clinical programs that include new treatments for PCP, malaria, and African sleeping sickness, and a well-defined, expanding library of compounds targeting fungal infections, HCV and other serious diseases.  Immtech holds an exclusive worldwide license to certain patents and patent applications related to technology and products derived from a proprietary pharmaceutical platform.  The Company has worldwide rights to commercialize and sublicense such patented technology, including a large library of well-defined compounds from which a pipeline of therapeutic products could be developed.

 

The Company holds worldwide patents and patent applications, and licenses and rights to license technology, primarily from a scientific consortium that has granted to the Company exclusive rights to commercialize products from, and license rights to the technology.  The scientific consortium includes scientists from The University of North Carolina at Chapel Hill (“UNC-CH”), Georgia State University (“Georgia State”), Duke University (“Duke University”) and Auburn University (“Auburn University”) (collectively, the “Scientific Consortium”).  The Company is a development stage enterprise and, since its inception on October 15, 1984, has engaged in research and development programs, expanded its network of scientists and scientific advisors and

 

 

-7-

---

 

licensing technology agreements, and work to commercialize the aromatic cation pharmaceutical technology platform (the Company acquired its rights to the aromatic cation technology platform in 1997 and promptly thereafter commenced development of its current programs).  The Company uses the expertise and resources of strategic partners and third parties in a number of areas, including:  (i) laboratory research, (ii) animal and human trials and (iii) manufacture of pharmaceutical drugs.

 

The Company does not have any products currently available for sale, and no products are expected to be commercially available for sale until after March 31, 2008, if at all.

 

Since inception, the Company has incurred accumulated net losses of approximately $107,283,000.  Management expects the Company will continue to incur significant losses during the next several years as the Company continues development activities, clinical trials and commercialization efforts.  In addition, the Company has various research and development agreements with third parties and is dependent upon such parties’ abilities to perform under these agreements.  There can be no assurance that the Company’s activities will lead to the development of commercially viable products.  The Company’s operations to date have consumed substantial amounts of cash.  The negative cash flow from operations is expected to continue in the foreseeable future.  The Company believes it will require substantial additional funds to commercialize its drug candidates.  The Company’s cash requirements may vary materially from those now planned when and if the following become known: results of research and development efforts, results of clinical testing, responses to grant requests, formation and development of relationships with strategic partners, changes in the focus and direction of development programs, competitive and technological advances, requirements in the regulatory process and other factors.  Changes in circumstances in any of the above areas may require the Company to allocate substantially more funds than are currently available or than management intends to raise.

 

Management believes the Company’s existing unrestricted cash and cash equivalents, and the grants received or awarded and awaiting disbursement of, will be sufficient to meet the Company’s planned expenditures through at least the next twelve months, although there can be no assurance the Company will not require additional funds.  Management may seek to satisfy future funding requirements through public or private offerings of securities, by collaborative or other arrangements with pharmaceutical or biotechnology companies or from other sources or by issuance of debt.

 

The Company’s ability to continue as a going concern in its present form is dependent upon its ability to generate sufficient funds to meet its obligations as they become due, have the United States Food and Drug Administration (the “FDA”) remove the clinical hold on the pafuramidine development program, complete the development and commercialization of drug candidates and, ultimately, to generate sufficient revenues for profitable operations.  Management’s plans for the forthcoming year, in addition to normal operations, include continuing financing efforts, obtaining additional research grants and entering into research and development agreements with other entities.

 

 

-8-

---

 

Principles of Consolidation – The consolidated financial statements include the accounts of Immtech Pharmaceuticals, Inc. and its wholly owned subsidiaries.  All intercompany balances and transactions have been eliminated.

 

Revenue Recognition – Grants to perform research have been the Company’s primary source of revenue and are generally granted to support research and development activities for specific projects or drug candidates.  Revenue related to grants to perform research and development is recognized as earned based on the performance requirements of the specific grant.  Upfront cash payments from research and development grants are reported as deferred revenue until such time as the research and development activities covered by the grant are performed.

 

Revenue from licensing arrangements is recorded when earned based on the performance requirements of the contract.  Nonrefundable upfront license fees, for product candidates where the Company is providing continuing services related to product development, are deferred and recognized as revenue over the development period or as the Company provides services required under the agreement.  The timing and amount of revenue the Company recognizes from licenses, either from upfront fees or milestones where the Company is providing continuing services related to product development, is dependent upon the Company’s estimates of filing dates.  As product candidates move through the development process, it is necessary to revise these estimates to consider changes to the product development cycle, such as changes in the clinical development plan, regulatory requirements, or various other factors, many of which may be outside of the Company’s control.  The impact on revenue changes in the Company’s estimates and the timing thereof, is recognized prospectively over the remaining estimated product development period.

 

Net Income (Loss) Per Share – Net income (loss) per share is calculated in accordance with Statement of Financial Accounting Standard (“SFAS”) No. 128, “Earnings Per Share.”  Basic net income (loss) and diluted net income (loss) per share are computed by dividing net income (loss) attributable to common stockholders by the weighted average number of common shares outstanding.  Diluted net income per share, when applicable, is computed by dividing net income attributable to common stockholders by the weighted average number of common shares outstanding increased by the number of potential dilutive common shares based on the treasury stock method.  Diluted net loss per share was the same as the basic net loss per share for the three and nine month periods ended December 31, 2007 and December 31, 2006, as none of the Company’s outstanding common stock options, warrants and the conversion features of Series A, B, C, D and E Convertible Preferred Stock were dilutive.

 

Stock-Based Compensation – Effective April 1, 2006, the Company adopted SFAS No. 123(R), “Share-Based Payment,” using the modified prospective method.  SFAS No. 123(R) requires entities to recognize the cost of employee services in exchange for awards of equity instruments based on the grant-date fair value of those awards (with limited exceptions).  The cost, based on the estimated number of awards that are expected to vest, will be recognized over the period during which the employee is required to provide the services in exchange for the award.  No compensation cost is recognized for

 

-9-

---

 

awards for which employees do not render the requisite service.  Upon adoption, the grant-date fair value of employee share options and similar instruments was estimated using the Black-Scholes valuation model.  The Black-Scholes valuation requires the input of highly subjective assumptions, including the expected life of the stock-based award and stock price volatility.  The assumptions used are management’s best estimates, but the estimates involve inherent uncertainties and the application of management’s judgment.  As a result, if other assumptions had been used, the recorded and pro forma stock-based compensation expense could have been materially different from that depicted in the financial statements.

 

Segment Reporting – The Company is a development stage pharmaceutical company that operates as one segment.

 

New Accounting Standard – The Company adopted FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes,” (“FIN 48”) on April 1, 2007.  The adoption of FIN 48 did not have an impact.  At the adoption date and as of December 31, 2007, the Company does not have a liability for uncertain tax benefits.  The Company does not presently expect any reasonably possible material change to the estimated amount of liability associated with its uncertain tax positions during the next twelve months.

 

The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions.  Periods subject to examination for the Company’s federal tax return are the 1991 through 2007 tax years.  In addition, open tax years related to state jurisdictions remain subject to examination but are not considered material.

 

New Accounting Standard – In September 2006, the FASB issued Statement No. 157 (“SFAS 157”), “Fair Value Measurements.”  SFAS 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles, and expands disclosures about fair value measurements.  SFAS 157 is effective for us in fiscal year 2009.  The Company is currently assessing the impact of the adoption of this statement.

 

New Accounting Standard – In February 2007, the FASB issued Statement No. 159 (“SFAS 159”), “Fair Value Option for Financial Assets and Financial Liabilities.”  SFAS 159 establishes the irrevocable option to elect to carry certain financial assets and liabilities at fair value, with changes in fair value recorded in earnings.  SFAS 159 is effective for us in fiscal year 2009.  The Company is currently assessing the impact of the adoption of this statement.

 

3.	STOCKHOLDERS’ EQUITY

 

On January 7, 2004, the stockholders of the Company approved an increase in the number of authorized common stock from 30 million to 100 million shares.  On June 14, 2004, the Company filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation implementing, among other things,

 

-10-

---

 

the approved authorized 70 million share common stock increase from 30 million to 100 million shares of common stock.

 

Series A Convertible Preferred Stock - On February 14, 2002, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 320,000 shares of the Company’s 5,000,000 authorized shares of preferred stock as Series A Convertible Preferred Stock, $0.01 par value, with a stated value of $25.00 per share.  Dividends accrue at a rate of 6.0% per annum on the $25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding.  The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined.  Included in the carrying value of the Series A Convertible Preferred Stock in the accompanying condensed consolidated balance sheets are $16,935 and $39,783 of accrued preferred stock dividends at December 31, 2007 and March 31, 2007, respectively.  Each share of Series A Convertible Preferred Stock may be converted by the holder at any time into shares of our common stock at a conversion rate determined by dividing the $25.00 stated value, plus any accrued and unpaid dividends (the “Liquidation Price”), by a $4.42 conversion price (the “Conversion Price A”), subject to certain adjustments, as defined in the Series A Certificate of Designation.  On October 17, 2007, the Company issued 5,106 shares of common stock and paid $108 in lieu of fractional common shares as dividends on the preferred shares.  On October 15, 2006, the Company issued 7,929 shares of common stock and paid $83 in lieu fractional common shares as dividends on the preferred shares.  On April 15, 2007, the Company issued 6,308 shares of common stock and paid $87 in lieu of fractional common shares as dividends on the preferred shares. On April 15, 2006, the Company issued 5,547 shares of common stock and paid $47 in lieu of fractional common shares as dividends on the preferred shares.  During the three month periods ended December 31, 2007 and 2006, there were no conversions of Series A Convertible Preferred Stock.  During the nine month periods ended December 31, 2007 and 2006, certain preferred stockholders converted 1,000 and 2,400 shares of Series A Convertible Preferred Stock, including accrued dividends, for 5,701 and 13,690 shares of common stock, respectively.

 

The Company may at any time require that any or all outstanding shares of Series A Convertible Preferred Stock be converted into shares of the Company’s common stock, provided that the shares of common stock into which the Series A Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined.  The number of shares of common stock to be received by the holders of the Series A Convertible Preferred Stock upon a mandatory conversion by the Company is determined by (i) dividing the Liquidation Price by the Conversion Price A, provided that the closing bid price for the Company’s common stock exceeds $9.00 for 20 consecutive trading days within 180 days prior to notice of conversion, as defined, or (ii) if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price A.  The Conversion Price is subject to certain adjustments, as defined in the Series A Certificate of Designation.

 

 

-11-

---

 

The Company may at any time, upon 30 days’ notice, redeem any or all outstanding shares of the Series A Convertible Preferred Stock by payment of the Liquidation Price to the holder of such shares, provided that the holder does not convert the Series A Convertible Preferred Stock into shares of common stock during the 30 day period.  The Series A Convertible Preferred Stock has a preference in liquidation equal to $25.00 per share, plus any accrued and unpaid dividends, over the common stock and is pari passu with all other outstanding series of preferred stock.  Each issued and outstanding share of Series A Convertible Preferred Stock shall be entitled to 5.6561 votes (subject to adjustment) with respect to any and all matters presented to the Company’s stockholders for their action or consideration.  Except as provided by law or by the provisions establishing any other series of preferred stock, Series A Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

 

Series B Convertible Preferred Stock - On September 25, 2002, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 240,000 shares of the Company’s 5,000,000 authorized shares of preferred stock as Series B Convertible Preferred Stock, $0.01 par value, with a stated value of $25.00 per share.  Dividends accrue at a rate of 8.0% per annum on the $25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding.  The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined.  Included in the carrying value of the Series B Convertible Preferred Stock in the accompanying condensed consolidated balance sheets are $4,526 and $12,021 of accrued preferred stock dividends as of December 31, 2007 and March 31, 2007, respectively.  Each share of Series B Convertible Preferred Stock may be converted by the holder at any time into shares of common stock at a conversion rate determined by dividing the $25.00 stated value, plus any accrued and unpaid dividends (the “Liquidation Price”), by a $4.00 conversion price (the “Conversion Price B”), subject to certain adjustments, as defined in the Series B Certificate of Designation.  On October 17, 2007, the Company issued 1,682 shares of common stock and paid $35 in lieu of fractional common shares as dividends on the preferred shares.  On October 15, 2006, the Company issued 2,542 shares of common stock and paid $26 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2007, the Company issued 2,040 shares of common stock and paid $30 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2006, the Company issued 1,703 shares of common stock and paid $31 in lieu of fractional common shares as dividends on the preferred shares.  During the three month and nine month periods ended December 31, 2007, a preferred shareholder converted 2,000 shares of Series B Convertible Preferred Stock, including accrued dividends, for 12,574 shares of common stock.  During the three and nine month periods ended December 31, 2006, there were no conversions.

 

The Company may at any time require that any or all outstanding shares of Series B Convertible Preferred Stock be converted into shares of the Company’s common stock, provided that the shares of common stock into which the Series B Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined.  The number of shares of common stock to be received by the holders of the

 

-12-

---

 

Series B Convertible Preferred Stock upon a mandatory conversion by the Company is determined by (i) dividing the Liquidation Price by the Conversion Price B, provided that the closing bid price for the Company’s common stock exceeds $9.00 for 20 consecutive trading days within 180 days prior to notice of conversion, as defined, or (ii) if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price B.  The Conversion Price B is subject to certain adjustments, as defined in the Series B Certificate of Designation.

 

The Company may at any time, upon 30 days’ notice, redeem any or all outstanding shares of the Series B Convertible Preferred Stock by payment of the Liquidation Price to the holder of such shares, provided that the holder does not convert the Series B Convertible Preferred Stock into shares of common stock during the 30 day period.  The Series B Convertible Preferred Stock has a preference in liquidation equal to $25.00 per share, plus any accrued and unpaid dividends over the common stock and is pari passu with all other outstanding series of preferred stock.  Each issued and outstanding share of Series B Convertible Preferred Stock shall be entitled to 6.25 votes (subject to adjustment) with respect to any and all matters presented to the Company’s stockholders for their action or consideration.  Except as provided by law or by the provisions establishing any other series of preferred stock, Series B Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

 

Series C Convertible Preferred Stock - On June 6, 2003, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 160,000 shares of the Company’s 5,000,000 authorized shares of preferred stock as Series C Convertible Preferred Stock, $0.01 par value, with a stated value of $25.00 per share.  Dividends accrue at a rate of 8.0% per annum on the $25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding.  The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined.  Included in the carrying value of the Series C Convertible Preferred Stock in the accompanying condensed consolidated balance sheets are $19,489 and $41,945 of accrued preferred stock dividends as of December 31, 2007 and March 31, 2007, respectively.  Each share of Series C Convertible Preferred Stock may be converted by the holder at any time into shares of common stock at a conversion rate determined by dividing the $25.00 stated value, plus any accrued and unpaid dividends (the “Liquidation Price”), by a $4.42 conversion price (the “Conversion Price C”), subject to certain adjustments, as defined in the Series C Certificate of Designation.  On October 17, 2007, the Company issued 5,694 shares of common stock and paid $75 in lieu of fractional common shares as dividends on the preferred shares.  On October 15, 2006, the Company issued 8,602 shares of common stock and paid $62 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2007, the Company issued 6,900 shares of common stock and paid $99 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2006, the Company issued 5,761 shares of common stock and paid $95 in lieu of fractional common shares as dividends on the preferred shares.  During the three and nine month periods ended December 31, 2007 and 2006, there were no conversions.

 

 

-13-

---

 

The Company may at any time require that any or all outstanding shares of Series C Convertible Preferred Stock be converted into shares of the Company’s common stock, provided that the shares of common stock into which the Series C Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined.  The number of shares of common stock to be received by the holders of the Series C Convertible Preferred Stock upon a mandatory conversion by the Company is determined by (i) dividing the Liquidation Price by the Conversion Price C provided that the closing bid price for the Company’s common stock exceeds $9.00 for 20 consecutive trading days within 180 days prior to notice of conversion, as defined, or (ii) if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price C.  The Conversion Price C is subject to certain adjustments, as defined in the Series C Certificate of Designation.

 

The Company may at any time, upon 30 days’ notice, redeem any or all outstanding shares of the Series C Convertible Preferred Stock by payment of the Liquidation Price to the holder of such shares, provided that the holder does not convert the Series C Convertible Preferred Stock into shares of common stock during the 30 day period. The Series C Convertible Preferred Stock has a preference in liquidation equal to $25.00 per share, plus any accrued and unpaid dividends, over the common stock and is pari passu with all other outstanding series of preferred stock.  Each issued and outstanding share of Series C Convertible Preferred Stock shall be entitled to 5.6561 votes (subject to adjustment) with respect to any and all matters presented to the Company’s stockholders for their action or consideration.  Except as provided by law or by the provisions establishing any other series of preferred stock, Series C Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

 

Series D Convertible Preferred Stock – On January 15, 2004, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 200,000 shares of the Company’s 5,000,000 authorized shares of preferred stock as Series D Convertible Preferred Stock, $0.01 par value, with a stated value of $25.00 per share.  Dividends accrue at a rate of 6.0% per annum on the $25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding.  The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined. Included in the carrying value of the Series D Convertible Preferred Stock in the accompanying condensed consolidated balance sheets are $36,925 and $80,914 of accrued preferred stock dividends as of December 31, 2007 and March 31, 2007, respectively.  Each share of Series D Convertible Preferred Stock may be converted by the holder at any time into shares of common stock at a conversion rate determined by dividing the $25.00 stated value, plus any accrued and unpaid dividends (the “Liquidation Price”), by a $9.00 conversion price (the “Conversion Price D”), subject to certain adjustments, as defined in the Series D Certificate of Designation. On October 17, 2007, the Company issued 10,804 shares of common stock and paid $140 in lieu of fractional common shares as dividends on the preferred share.  On October 15, 2006, the Company issued 16,611 shares of common stock and paid $86 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2007, the Company issued 13,334 shares of

-14-

---

common stock and paid $95 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2006, the Company issued 11,134 shares of common stock and paid $79 in lieu of fractional common shares as dividends on the preferred shares.  During the three month period ended December 31, 2007, there were no conversions.  During the nine month period ended December 31, 2007, certain preferred stockholders converted 2,000 shares of Series D Convertible Preferred Stock, including accrued dividends, for 5,653 shares of common stock, respectively. During the three and nine month periods ended December 31, 2006, there were no conversions.

 

The Company may at any time, require that any or all outstanding shares of Series D Convertible Preferred Stock be converted into shares of our common stock, provided that the shares of common stock into which the Series D Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined.  The number of shares of common stock to be received by the holders of the Series D Convertible Preferred Stock upon a mandatory conversion by the Company is determined by (i) dividing the Liquidation Price by the Conversion Price D provided that the closing bid price for the Company’s common stock exceeds $18.00 for 20 consecutive trading days within 180 days prior to notice of conversion, as defined, or (ii) if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price D.  The Conversion Price D is subject to certain adjustments, as defined in the Certificate of Designation.

 

The Series D Convertible Preferred Stock has a preference in liquidation equal to $25.00 per share, plus any accrued and unpaid dividends, over the common stock and is pari passu with all other series of preferred stock.  Each issued and outstanding share of Series D Convertible Preferred Stock shall be entitled to 2.7778 votes (subject to adjustment) with respect to any and all matters presented to the Company’s stockholders for their action or consideration. Except as provided by law or by the provisions establishing any other series of preferred stock, Series D Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

 

Series E Convertible Preferred Stock –On December 13, 2005, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware designating 167,000 shares of the Company’s 5,000,000 authorized shares of preferred stock as Series E Convertible Preferred Stock, $0.01 par value, with a stated value of $25.00 per share.  Dividends accrue at a rate of 6.0% per annum on the $25.00 stated value per share and are payable semi-annually on April 15 and October 15 of each year while the shares are outstanding.  The Company has the option to pay the dividend either in cash or in equivalent shares of common stock, as defined.  Included in the carrying value of the Series E Convertible Preferred Stock in the accompanying condensed consolidated balance sheets are $31,639 and $76,116 of accrued preferred stock dividends as of December 31, 2007 and March 31, 2007, respectively.  Each share of Series E Convertible Preferred Stock may be converted by the holder at any time into shares of common stock at a conversion rate determined by dividing the $25.00 stated value, plus any accrued and unpaid dividends (the “Liquidation Price”), by a $7.04 conversion price (the “Conversion Price E”), subject to certain adjustments, as defined in

 

-15-

---

 

the Series E Certificate of Designation.  On October 17, 2007, the Company issued 9,995 shares of common stock and paid $149 in lieu of fractional common shares as dividends on the preferred shares.  On October 15, 2006, the Company issued 15,670 shares of common stock and paid $111 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2007, the Company issued 12,531 shares of common stock and paid $132 in lieu of fractional common shares as dividends on the preferred shares.  On April 15, 2006, the Company issued 8,819 shares of common stock and paid $135 in lieu of fractional common shares as dividends on the preferred shares.  During the three and nine month periods ended December 31, 2007, certain preferred stockholders converted 8,000 and 11,600 shares of Series E Convertible Preferred Stock, including accrued dividends, for 28,632 and 41,604 shares of common stock, respectively.  During the three month period ended December 31, 2006, a preferred shareholder converted 400 shares of Series E Convertible Preferred Stock, including accrued dividends, for 1,424 shares of common stock.  During the nine month period ended December 31, 2006, certain preferred stockholders converted 46,400 shares of Series E Convertible Preferred Stock, including accrued dividends, for 165,271 shares of common stock.

 

The Company may at any time, require that any or all outstanding shares of Series E Convertible Preferred Stock be converted into shares of our common stock, provided that the shares of common stock into which the Series E Convertible Preferred Stock are convertible are registered pursuant to an effective registration statement, as defined.  The number of shares of common stock to be received by the holders of the Series E Convertible Preferred Stock upon a mandatory conversion by us is determined by (i) dividing the Liquidation Price by the Conversion Price E provided that the closing bid price for the Company’s common stock exceeds $10.56 for 20 out of 30 consecutive trading days within 180 days prior to notice of conversion, as defined, or (ii) if the requirements of (i) are not met, the number of shares of common stock is determined by dividing 110% of the Liquidation Price by the Conversion Price E.  The Conversion Price E is subject to certain adjustments, as defined in the Certificate of Designation.

 

The Series E Convertible Preferred Stock has a preference in liquidation equal to $25.00 per share, plus any accrued and unpaid dividends, over the common stock and is parri passu with all other outstanding series of preferred stock.  Each issued and outstanding share of Series E Convertible Preferred Stock is entitled to 3.5511 votes (subject to adjustment) with respect to any and all matters presented to the Company’s stockholders for their action or consideration. Except as provided by law or by the provisions establishing any other series of preferred stock, Series E Convertible Preferred stockholders and holders of any other outstanding preferred stock shall vote together with the holders of common stock as a single class.

 

The Company will, on December 13, 2008, at the Company’s election, (i) redeem the Series E Convertible Preferred Stock plus any accrued and unpaid interest for cash, (ii) convert the Series E Convertible Preferred Stock and any accrued and unpaid interest into common stock, or (iii) redeem and convert the Series E Convertible Preferred Stock in any combination of (i) or (ii).

 

 

-16-

---

 

Common Stock –On May 26, 2006, restricted shares in the amount of 5,000 shares of common stock were issued and expensed with a grant date value of approximately $36,000 to Tulane University as part of the Tulane License Agreement granting to us an exclusive license to develop, manufacture and commercialize a group of four – aminoquinoline drugs for treatment, prophylaxis and diagnosis of infectious diseases.

 

On May 26, 2006, restricted shares in the amount of 5,000 shares of common stock were issued and expensed with a grant date value of approximately $36,000 to T. Stephen Thompson as part of his retirement and consulting agreement dated May 1, 2006.

 

On November 28, 2006, restricted shares in the amount of 80,000 shares of common stock were issued to China Pharmaceutical Investments Limited (“China Pharmaceutical”) as part of the agreement signed August 28, 2006 between Immtech Pharmaceuticals, Inc. and China Pharmaceutical.  China Pharmaceutical achieved milestone payments of common stock for identification of a site deemed suitable by the Company for building a pharmaceutical plant and for completing the feasibility study to be submitted to the appropriate governmental agencies.

 

Warrants – During the three and nine month periods ended December 31, 2007, warrants to purchase 30,000 and 78,312 shares of common stock were exercised, resulting in proceeds to the Company of $187,200 and $482,937, respectively.  During the three month period ended December 31, 2006, there were no warrants exercised.  During the nine month period ended December 31, 2006, warrants to purchase 5,000 shares of common stock were exercised, resulting in proceeds to the Company of $30,000.

 

In connection with services rendered to us, effective July 17, 2007, the Company issued to an investor relations firm, warrants to purchase 30,000 shares of our common stock.  The warrants are exercisable at $9.00 per share.  The warrants are exercisable through July 17, 2011 as follows: (i) 10,000 vest immediately, (ii) 10,000 vest upon the Company’s stock trading at or above $10.00 per share for 20 consecutive trading days and (iii) 10,000 vest upon the Company’s stock trading at or above $12.00 per share for 20 consecutive trading days.  The warrants have been expensed using a grant date value as calculated using the Black-Scholes valuation model of approximately $118,000.

 

In connection with a consulting agreement, the Company issued warrants on September 10, 2007 to purchase 50,000 shares of common stock.  The warrants are exercisable at $10.00 per share.  The warrants are exercisable through September 10, 2010.  The warrants have been expensed using a grant date value as calculated using the Black-Scholes valuation model of approximately $172,000.

 

Incentive Stock Programs – At the stockholders’ meeting held November 29, 2007, the stockholders approved the 2007 Stock Incentive Plan which increased the number of shares of common stock reserved for issuance an additional 1,500,000 shares.  Options granted under the 2000 Stock Incentive Plan that expire are available to be reissued.  During the nine month periods ended December 31, 2007 and 2006, 83,746 and 103,430 options, respectively, previously granted under the 2000 Stock Incentive Plan expired and were available to be reissued.  During the three month period ended December 31, 2007,

-17-

---

the Company issued 312,650 options to purchase shares of common stock.  During the three month period ended December 31, 2006, the Company issued 365,000 options to purchase shares of common stock. During the nine month periods ended December 31, 2007 and 2006, the Company issued 487,318 and 421,000 options, respectively, to purchase shares of common stock.  Additionally, the Company granted 5,000 restricted stock awards in the period ended June 30, 2006.  As of December 31, 2007, there were a total of 1,535,941 shares available for grant. The purchase price of shares must be at least equal to the fair market value of the common stock on the date of grant, and the maximum term of an option is 10 years.  The options generally vest over periods ranging from 0 to 4 years.

 

The Company recognized approximately $725,000 and $1,829,000 of compensation cost for the three and nine month periods ended December 31, 2007, and approximately $574,000 and $1,736,000 for the three and nine month periods ended December 31, 2006. During the three month period ended December 31, 2007, 7,000 options were exercised on a cashless basis resulting in 4,254 common shares being issued, and 972 options were exercised with an exercise price of $2.55, resulting in proceeds to the Company of approximately $2,479.  During the three and nine month periods ended December 31, 2006, 29,000 and 80,605 options were exercised on a cashless basis resulting in 12,736 and 61,085 common shares being issued, respectively.

 

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model.  The Company uses historical data regarding stock option exercise behaviors to estimate the expected term of options granted (based on the period of time that options granted are expected to be outstanding).  Expected implied volatility is based on the volatility of the Company’s exchange traded options for the Company’s common stock.  The risk-free interest rate is based on the U.S. treasury security rate in effect over the estimated life of the option. There is no dividend yield.  The following weighted-average assumptions were used in calculating the fair value of stock options granted during the three and nine month periods ended December 31, 2007 and 2006.

 

	Three Months			Nine Months
	Ended December 31,			Ended December 31,
	2007	2006		2007	2006
Risk free interest rate	4.25%	4.78%		4.41%	4.80%
Average life of options (years)	10.0	10.0		10.0	9.5
Volatility	62%	80%		67%	78%
Dividend yield	0	0		0	0

 

 

-18-

---

 

A summary of stock option activity as of and for the nine month period ended December 31, 2007, is presented below:

 

		Shares				Exercise Price Per Share (*)				Remaining Contractual Term(*) in Years
Outstanding at March 31, 2007			1,800,609			$	8.92
Granted			487,318				6.57
Exercised			(27,091	)			1.08
Forfeited or expired			(81,000	)			10.95
Outstanding at December 31, 2007			2,179,836				8.41				7.04
Exercisable at December 31, 2007			1,573,882				9.14				6.55

(*) Weighted-average

 

The weighted-average grant date fair value of options granted during the nine month periods ended December 31, 2007 and 2006 was $6.57 and $5.96, respectively.  The intrinsic value of options exercised during the nine month periods ended December 31, 2007 and 2006 was approximately $174,000 and $466,000, respectively.  The intrinsic value of stock options outstanding at the nine month periods ended December 31, 2007 and 2006 was approximately $347,000 and $1,715,000, respectively.

 

As of December 31, 2007, there was approximately $2,730,000 of unrecognized compensation cost related to non-vested stock option compensation arrangements granted under the 2000 and 2007 Plans that are expected to be recognized as a charge to earnings over a weighted-average period of 1.3 years.  As of December 31, 2007, 1,734,203 options have vested or are expected to vest with a weighted-average exercise price of $10.85, a weighted-average remaining life of 7.11 years, and with an intrinsic value of approximately $330,000.

 

4.	COLLABORATIVE RESEARCH AND DEVELOPMENT ACTIVITIES

 

The Company earns revenue under various collaborative research agreements.  Under the terms of these arrangements, the Company generally has agreed to perform best efforts research and development and, in exchange, the Company may receive advanced cash funding, an allowance for management overhead, and may also earn additional fees for the attainment of certain milestones.

 

The Company initially acquired its rights to the aromatic cation technology platform developed by a consortium of universities consisting of UNC-CH, Georgia State University, Duke University and Auburn University pursuant to an agreement, dated January 15, 1997 (as amended, the “Consortium Agreement”) among the Company, UNC-CH and a third-party (to which each of the other members of the scientific consortium shortly thereafter joined) (the “original licensee”).  The Consortium Agreement commits the parties to collectively research, develop, finance the research and development of, manufacture and market both the technology and compounds owned by the scientific consortium and previously licensed or optioned to the original licensee and licensed to the Company  in accordance with the Consortium Agreement (the “Current Compounds”), and all technology and compounds developed by the scientific consortium

 

-19-

---

 

after January 15, 1997, through use of Company-sponsored research funding or National Cooperative Drug Development grant funding made available to the scientific consortium (the “Future Compounds” and, collectively with the Current Compounds, the “Compounds”).

 

The Consortium Agreement contemplated that upon the completion of our initial public offering (“IPO”) of shares of its common stock with gross proceeds of at least $10,000,000 by April 30, 1999, the Company, with respect to the Current Compounds, and UNC-CH, (on behalf of the Scientific Consortium), with respect to Current Compounds and Future Compounds, would enter into license agreements for the intellectual property rights relating to the Compounds pursuant to which the Company would pay royalties and other payments based on revenues received for the sale of products based on the Compounds.

 

The Company completed an IPO on April 26, 1999, with gross proceeds in excess of $10,000,000 thereby earning a worldwide license and exclusive rights to commercially use, manufacture, have manufactured, promote, sell, distribute, or otherwise dispose of any products based directly or indirectly on all of the Current Compounds and Future Compounds.

 

As a result of the closing of the IPO, the Company issued an aggregate of 611,250 shares of common stock, of which 162,500 shares were issued to the Scientific Consortium and 448,750 shares were issued to the original licensee or persons designated by the original licensee.

 

As contemplated by the Consortium Agreement, on January 28, 2002, the Company entered into a License Agreement with the Scientific Consortium whereby the Company received the exclusive license to commercialize the aromatic cation technology platform and compounds developed or invented by one or more of the Consortium scientists after January 15, 1997, and which also incorporated into such License Agreement the Company’s existing license with the Scientific Consortium with regard to the Current Compounds.  Also pursuant to the Consortium Agreement, the original licensee transferred to the Company the worldwide license and exclusive right to commercially use, manufacture, have manufactured, promote, sell, distribute or otherwise dispose of any and all products based directly or indirectly on aromatic cations developed by the Scientific Consortium on or prior to January 15, 1997 and previously licensed (together with related technology and patents) to the third-party.

 

The Consortium Agreement provides that the Company is required to pay to UNC-CH on behalf of the Scientific Consortium reimbursement of patent and patent-related fees, certain milestone payments and royalty payments based on revenue derived from the Scientific Consortium’s aromatic cation technology platform.  Each month on behalf of the inventor scientist or university, as the case may be, UNC-CH submits an invoice to the Company for payment of patent-related fees related to current compounds or future compounds incurred prior to the invoice date.  The Company is also required to make milestone payments in the form of the issuance of 100,000 shares of its common stock to the Consortium when it files its first initial New Drug Application (“NDA”) or an

 

-20-

---

 

Abbreviated New Drug Application (“ANDA”) based on Consortium technology.  The Company is also required to pay to UNC-CH on behalf of the Scientific Consortium (other than Duke University) (i) royalty payments of up to 5% of our net worldwide sales of “current products” and “future products” (products based directly or indirectly on current compounds and future compounds, respectively) and (ii) a percentage of any fees the Company receives under sublicensing arrangements.  With respect to products or licensing arrangements emanating from Duke University technology, the Company is required to negotiate in good faith with UNC-CH (on behalf of Duke University) royalty, milestone or other fees at the time of such event, consistent with the terms of the Consortium Agreement.

 

Under the License Agreement, the Company must also reimburse the cost of obtaining patents and assume liability for future costs to maintain and defend patents so long as the Company chooses to retain the license to such patents.

 

During the three and nine month periods ended December 31, 2007, the Company expensed approximately $180,000 and $583,000, respectively, of other payments to UNC-CH and certain other Scientific Consortium universities for patent related costs and other contracted research.  For the corresponding periods ended December 31, 2006, the Company expensed approximately $150,000 and $786,000, respectively. Included in accounts payable as of December 31, 2007 and March 31, 2007, were approximately $330,000, and $174,000, respectively, due to UNC-CH and certain other Scientific Consortium universities.

 

In November 2000, The Bill & Melinda Gates Foundation (“Foundation”) awarded a $15,114,000 grant to UNC-CH to develop new drugs to treat African sleeping sickness and leishmaniasis.  On March 29, 2001, UNC-CH entered into a clinical research subcontract agreement with the Company, whereby the Company was to receive up to $9,800,000, subject to certain terms and conditions, over a five year period to conduct certain clinical and research studies related to the Foundation Grant.

 

In April 2003, the Foundation awarded a supplemental grant of approximately $2,700,000 to UNC-CH for the expansion of phase IIB/III clinical trials to treat African sleeping sickness and improved manufacturing processes.  The Company has received, pursuant to the clinical research subcontract with UNC-CH, inclusive of its portion of the supplemental grant, a total amount of funding of approximately $11,700,000.  Grant funds paid in advance of the Company’s delivery of services are treated as restricted funds and must be segregated from other funds and used for the purposes specified. In March 2006, the Company amended and restated the clinical research subcontract with UNC-CH and UNC-CH in turn obtained an expanded funding commitment for the Company of approximately $13,601,000 from the Foundation.  Under the amended and restated agreement, the Company received on May 24, 2006 the first payment of approximately $5,649,000 of the five year approximately $13,601,000 contract. On November 2, 2007, the Company received a second payment of approximately $5,123,000 from the Consortium.

 

 

-21-

---

 

During the three and nine months ended December 31, 2007, approximately $1,335,000 and $2,639,000 was utilized for clinical and research purposes conducted and expensed, respectively.  During the three and nine months ended December 31, 2006, approximately $445,000 and $1,653,000 was utilized for clinical and research purposes conducted and expensed, respectively. The Company has recognized revenues of approximately $1,335,000 and $2,639,000 during the three and nine months ended December 31, 2007, respectively.  The Company has recognized revenues of approximately $445,000 and $2,583,000 during the three and nine months ended December 31, 2006, respectively.  The remaining amount (approximately $4,211,000 as of December 31, 2007) has been deferred and will be recognized as revenue over the term of the agreement as the services are performed.

 

On November 26, 2003, the Company entered into a testing agreement (“Testing Agreement”) with Medicines for Malaria Venture (“MMV”), a foundation established in Switzerland, and UNC, pursuant to which the Company, with the support of MMV and UNC-CH, conducted a proof of concept study of the dicationic first drug candidate pafuramidine for the treatment of malaria.

 

Under the terms of the Testing Agreement, MMV committed to pay for human clinical trials and, subject to certain milestones, regulatory preparation and filing costs for the approvals to market pafuramidine to treat malaria. In return for MMV’s funding, the Company is required, when selling malaria drugs derived from this research into “malaria-endemic countries,” as defined, to sell such drugs at affordable prices.  An affordable price is defined in the Testing Agreement to mean a price not to be less than the cost to manufacture and deliver the drugs plus administrative overhead costs (not to exceed 10% of the cost to manufacture) and a modest profit. There are no price constraints on product sales into non-malaria-endemic countries.  The Company must, however, pay to MMV a royalty not to exceed 7% of net sales, as defined, on product sales into non-malaria-endemic countries, until the amount funded under the Testing Agreement and amounts funded under a related discovery agreement between MMV and UNC-CH is refunded to MMV at face value.  The company and MMV agreed to terminate the Testing Agreement effective as of February 10, 2006.  The Company has received approximately $5,636,000 under this contract.

 

The Company recognized revenues of approximately $101,000 and $396,000 during the three and nine month periods ended September 30, 2006, respectively, for expenses incurred related to activities within the scope of the Testing Agreement.

 

On June 8, 2007, the Company entered into an exclusive licensing agreement pursuant to which the Company has licensed to Par Pharmaceutical Companies, Inc. (“Par”) commercialization rights in the United States of America to pafuramidine for the treatment of PCP in AIDS patients. The Company and Par may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk of developing PCP, including people living with HIV, cancer and other immunosuppressive conditions.

 

In return, the Company received an initial payment of $3 million.  Par will also pay the Company as much as $29 million in development milestones if pafuramidine advances

 

-22-

---

 

through ongoing Phase III clinical trials and FDA regulatory review and approval.  In addition to royalties on sales, the Company may receive up to $115 million in additional milestone payments on future sales and will retain the right to co-market pafuramidine in the United States of America.  The Company has also granted Par a right of first offer to enter into a license agreement with it if the Company determines that pafuramidine can be used for the treatment and/or prophylaxis of malaria.

 

On December 3, 2007, the Company entered into a licensing agreement with BioAlliance Pharma SA (“BioAlliance”) pursuant to which the Company granted BioAlliance and its affiliates an exclusive license to commercialize pafuramidine in Europe for the treatment of PCP in AIDS patients and African sleeping sickness. The Company also granted BioAlliance an option to commercialize pafuramidine in Europe for the prevention and treatment of malaria in travelers.  Pursuant to the license agreement, the Company received an initial payment of $3 million from BioAlliance, and it will receive an additional $13 million upon achieving certain regulatory and pricing milestones. In addition, the Company will receive an additional $10 million upon achieving certain sales milestones and will also receive double-digit royalties based on sales.

 

On December 20, 2007, the Food and Drug Administration (the “FDA”) informed the Company that it had placed all of the Company’s ongoing and projected clinical trials relating to the development of pafuramidine on clinical hold.  The FDA placed this clinical hold on the pafuramidine program after subjects in the Company’s Phase I safety study demonstrated abnormal liver function tests.  The affected subjects do not currently have any signs and symptoms related to the liver abnormalities and the Company’s clinical follow-up of the subjects remains ongoing.

 

The Company has reviewed data from the Phase I safety study with experts in liver disease, the Company’s consortium scientific advisors and governance council, and the Data Safety Monitoring Board.  Such experts will assist the Company in preparing a report to be submitted to the FDA reviewing data related to the liver function of subjects from the Company’s prior and currently suspended pafuramidine trials. In addition, the Company is developing a risk management plan to monitor potential liver abnormalities in pafuramidine studies related to African sleeping sickness, PCP and malaria, which will be submitted to the FDA as a part of the report.

 

Any resumption of the clinical trials for the pafuramidine program will require regulatory approval from the FDA.  There can be no assurance that the Company will be able to resume these trials or that, if resumed, whether and when they will be completed.  In addition, the Company may need to modify the clinical trial protocol, which could require it to repeat a trial or conduct additional trials.  Accordingly, if the Company is unable to resume its trials relating to pafuramidine or if the trials are delayed or modified, the Company’s business, operations and stock price may be adversely affected.

 

5.	NEUROCHEM ARBITRATION

 

On June 9, 2006, the International Court of Arbitration of the ICC notified the parties that (i) the Arbitral Panel found that Neurochem breached the testing agreement and awarded

 

-23-

---

 

Immtech approximately $1.9 million in damages and attorneys' fees and costs, and (ii) denied all of Neurochem's claims against Immtech. On July 10, 2006, Immtech requested that the Arbitral Panel make certain corrections to the Award. On or about September 27, 2006, Immtech received an Addendum to the Final Award, which did not alter the substance or amount of the Arbitral Panel’s Award. Subsequent to September 30, 2006, Neurochem disbursed funds representing the Final Award by the Arbitral Panel.

 

6.	LITIGATION

 

In October 2003, Gerhard Von der Ruhr and his son Mark (the “Von der Ruhr Plaintiffs”) filed a complaint in the United States District Court for the Northern District of Illinois against the Company and certain officers and directors alleging breaches of a stock lock-up agreement, option agreements and a technology license agreement by the Company. The Von der Ruhr Plaintiffs also alleged a claim for intentional interference with contractual relations by certain officers of the Company.  The complaint sought unspecified monetary damages and punitive damages, in addition to equitable relief and costs.  In a filing made in late February 2005, the Von der Ruhr Plaintiffs specified damages of approximately $44.5 million in damages.

 

In 2005, one of the breach of contract claims was dismissed upon the Company’s motion for summary judgment.  On October 26, 2006, a preliminary pre-trial conference was held and the court granted the Company’s motions in limine to exclude plaintiffs’ damage claim for lost profits and prohibited plaintiff from offering expert testimony at trial on this issue.  The court subsequently granted a motion to sever the trial on Count V, regarding the technology license agreement, from the trial on the remaining counts. The trial on the remaining counts concluded on December 7, 2007, and a jury returned a verdict against the Company and certain officers and directors for a total amount of $361,704.90. The Company immediately filed a motion with the court seeking to overturn the jury verdict, which the court subsequently denied. The Company is considering all options, including the filing of an appeal.

 

As a result of this ruling, the Company has accrued $362,000 as a reserve for settlement.

 

 

* * * * * *

 

 

-24-

---

 

                 Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Forward Looking Statements

 

Certain statements contained in this quarterly report and in the documents incorporated by reference herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements other than statements of historical fact may be deemed to be forward-looking statements.  Forward-looking statements frequently, but not always, use the words “may”, “intends”, “plans”, “believes”, “anticipates” or “expects” or similar words and may include statements concerning our strategies, goals and plans.  Forward-looking statements involve a number of significant risks and uncertainties that could cause our actual results or achievements or other events to differ materially from those reflected in such forward-looking statements.  Such factors include, among others described in this quarterly report, the following: (i) we are in an early stage of product development, (ii) the possibility that favorable relationships with collaborators cannot be established or, if established, will be abandoned by the collaborators before completion of product development, (iii) the possibility that we or our collaborators will not successfully develop any marketable products, (iv) the possibility that advances by competitors will cause our product candidates not to be viable, (v) uncertainties as to the requirement that a drug product be found to be safe and effective after extensive clinical trials and the possibility that the results of such trials, if completed, will not establish the safety or efficacy of our drug product candidates, (vi) risks relating to requirements for approvals by governmental agencies, such as the Food and Drug Administration, before products can be marketed and the possibility that such approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to market our product candidates successfully, (vii) the risk that our patents could be invalidated or narrowed in scope by judicial actions or that our technology could infringe upon the patent or other intellectual property rights of third parties, (viii) the possibility that we will not be able to raise adequate capital to fund our operations through the process of commercializing a successful product or that future financing will be completed on unfavorable terms, (ix) the possibility that any products successfully developed by us will not achieve market acceptance and (x) other risks and uncertainties that may not be described herein.  We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Results of Operations

 

With the exception of certain research funding agreements and certain grants, we have not generated any revenue from operations.  For the period from inception (October 15, 1984) to December 31, 2007, we incurred cumulative net losses of approximately $107,283,000.  We have incurred additional losses since such date and we expect to incur additional operating losses for the foreseeable future.  We expect that our cash sources for at least the next year will be limited to:

 

·	payments from foundations and other collaborators under arrangements that may be entered into in the future;

 

·	payments from license agreement milestones;

 

 

-25-

---

 

·	grants from the United States government and other governments and entities; and

 

·	the issuance of securities or borrowing of funds.

 

The timing and amounts of grant and payment revenues, if any, will likely fluctuate sharply and depend upon the achievement of specified milestones, and results of operations for any period may be unrelated to the results of operations for any other period.

 

Three Month Period Ended December 31, 2007 Compared with the Three Month Period Ended December 31, 2006.

 

Revenues under collaborative research and development, and license agreements were approximately $1,835,000 and $546,000 for the three month periods ended December 31, 2007 and December 31, 2006, respectively.  For the three month period ended December 31, 2007, we recognized revenues of approximately $1,335,000 related to a clinical research subcontract agreement between us and The University of North Carolina at Chapel Hill (“UNC-CH”),  approximately $387,000 related to the Par Pharmaceutical license agreement, and approximately $113,000 related to the BioAlliance license agreement while for the three month period ended December 31, 2006, revenues recognized of approximately $445,000 related to the abovementioned UNC-CH clinical research subcontract and $101,000 related to a grant from Medicines for Malaria Venture (“MMV”) to fund clinical studies and licensure of DB289 for treatment of malaria which has since lapsed.

 

The clinical research subcontract agreement relates to a grant from a philanthropic foundation (the “Foundation”) to UNC-CH to develop new drugs to treat African sleeping sickness and leishmaniasis.  MMV also receives funding from the Foundation.  Grant and research and development agreement revenue is recognized as completed under the terms of the respective agreements, according to Company estimates.  Grant and research and development funds received prior to completion under the terms of the respective agreements are recorded as deferred revenues.

 

Revenue from licensing arrangements is recorded when earned based on the performance requirements of the contract.  Nonrefundable upfront license fees, for product candidates where the Company is providing continuing services related to product development, are deferred and recognized as revenue over the development period or as the Company provides services required under the agreement.  The timing and amount of revenue the Company recognizes from licenses, either from upfront fees or milestones where the Company is providing continuing services related to product development, is dependent upon the Company’s estimates of filing dates.

 

Research and development expenses increased to approximately $4,214,000 from $1,862,000 for the three month periods ended December 31, 2007 and December 31, 2006, respectively.  Expenses relating to the UNC-CH subcontract, increased to approximately $1,335,000 in the three month period ended December 31, 2007 from approximately $445,000 in the three month period ended December 31, 2006 while expenses relating to the MMV testing agreement decreased over the same periods to approximately zero from $104,000.  Contract services relating to non-MMV supported malaria trials increased to approximately $369,000 in the three

 

-26-

---

 

month period ended December 31, 2007 from approximately $155,000 in the three month period ended December 31, 2006. Additionally, contract services relating to trials for treatment of PCP increased to approximately $1,438,000 from approximately $597,000 in the same periods.  Discovery contract research expenses increased to approximately $473,000 in the three month period ended December 31, 2007 from approximately $67,000 in the period ended December 31, 2006. Non-cash options expense under research and development decreased to approximately $136,000 in the three month period ended December 31, 2007 from approximately $206,000 in the three month period ended December 31, 2006.  Other research and development expenses increased approximately $175,000 from the three month period ended December 31, 2006 to the three month period ended December 31, 2007.

 

General and administrative expenses increased to approximately $2,926,000 from approximately $2,630,000 during the three month periods ended December 31, 2007, and December 31, 2006, respectively.  The increase was partly due to legal costs, which increased to approximately $519,000 in the three month period ended December 31, 2007, from approximately $280,000 in the three month period ended December, 2006, along with the booking of approximately $362,000 as a reserve for the settlement of the Von der Ruhr litigation.  Patent fees increased to approximately $126,000 in the three month period ended December 31, 2007 from approximately $105,000 in the three month period ended December 31, 2006. Non-cash general and administrative expenses decreased to approximately $588,000 in the three month period ended December 31, 2007, which is for expensing options, from approximately $932,000 in the three month period ended December 31, 2006, which relates to (i) approximately $368,000 for the expensing of options, and (ii) approximately $564,000 for the issuance of 80,000 common shares to China Pharmaceutical Investments Limited.

 

Our net loss increased to approximately $5,204,000 from approximately $3,829,000 during the three month periods ended December 31, 2007 and December 31, 2006, respectively.  The increase was primarily attributable to an increase in the research and development costs attributable to the trials for treatment of PCP.

 

Nine Month Period Ended December 31, 2007 Compared with the Nine Month Period Ended December 31, 2006.

 

Revenues under collaborative research and development agreements were approximately $3,692,000 and $2,979,000 for the nine month periods ended December 31, 2007 and December 31, 2006, respectively.  For the nine month period ended December 31, 2007, we recognized revenues of approximately $2,639,000 related to a clinical research subcontract agreement between us and UNC-CH, approximately $940,000 related to the Par Pharmaceutical license agreement, and approximately $113,000 related to the BioAlliance license agreement while for the nine month period ended December 31, 2006, revenues recognized of approximately $2,584,000 related to the abovementioned UNC-CH clinical research subcontract and $395,000 related to a grant from MMV to fund clinical studies and licensure of DB289 for treatment of malaria which has since lapsed.

 

The clinical research subcontract agreement relates to a grant from the Foundation to UNC-CH to develop new drugs to treat African sleeping sickness and leishmaniasis.  MMV also receives funding from the Foundation.  Grant and research and development agreement revenue is

 

-27-

---

 

recognized as completed under the terms of the respective agreements, according to Company estimates.  Grant and research and development funds received prior to completion under the terms of the respective agreements are recorded as deferred revenues.

 

Revenue from licensing arrangements is recorded when earned based on the performance requirements of the contract.  Nonrefundable upfront license fees, for product candidates where the Company is providing continuing services related to product development, are deferred and recognized as revenue over the development period or as the Company provides services required under the agreement.  The timing and amount of revenue the Company recognizes from licenses, either from upfront fees or milestones where the Company is providing continuing services related to product development, is dependent upon the Company’s estimates of filing dates.

 

Research and development expenses increased to approximately $8,415,000 from $6,086,000 for the nine month periods ended December 31, 2007 and December 31, 2006, respectively.  Expenses relating to the UNC-CH subcontract, increased to approximately $2,556,000 in the nine month period ended December 31, 2007 from approximately $1,653,000 in the nine month period ended December 31, 2006 while expenses relating to the MMV testing agreement decreased over the same periods to approximately $15,000 from $397,000.  Contract services relating to non-MMV supported malaria trials increased to approximately $1,151,000 in the nine month period ended December 31, 2007 from approximately $167,000 in the nine month period ended December 31, 2006. Additionally, contract services relating to trials for treatment of PCP decreased to approximately $2,233,000 from approximately $2,342,000 in the same periods. Discovery contract research expenses increased to approximately $1,079,000 in the nine month period ended December 31, 2007 from approximately $239,000 in the period ended December 31, 2006. Non-cash options expense under research and development decreased to approximately $369,000 in the nine month period ended December 31, 2007 from approximately $557,000 in the nine month period ended December 31, 2006.  Other research and development expenses increased approximately $281,000 from the nine month period ended December 31, 2006 to the nine month period ended December 31, 2007.

 

General and administrative expenses decreased to approximately $6,858,000 from approximately $7,213,000 during the nine month periods ended December 31, 2007, and December 31, 2006, respectively.  The decrease was partly due to lower business development costs, which decreased to approximately $12,000 in the nine month period ended December 31, 2007, from approximately $943,000 in the nine month period ended December 31, 2006.  Patent fees decreased to approximately $299,000 in the nine month period ended December 31, 2007 from approximately $611,000 in the nine month period ended December 31, 2006. Non-cash general and administrative expenses decreased to approximately $1,749,000 in the nine month period ended December 31, 2007, which includes (i) approximately $172,000 for the 50,000 warrants issued to a consultant, (ii) approximately $118,000 for the 30,000 warrants issued to an investor relations firm, and (iii) approximately $1,459,000 for expensing options, from approximately $1,814,000 in the nine month period ended December 31, 2006, which includes (i) approximately $36,000 for the issuance of 5,000 common shares to Tulane University, (ii) approximately $36,000 for the issuance of 5,000 common shares as part of a retirement and consulting agreement, (iii) approximately $564,000 for the issuance of 80,000 common shares to

 

-28-

---

 

China Pharmaceutical Investments Limited, and (iv) approximately $1,178,000 for expensing options.

 

Our net loss increased to approximately $11,199,000 from approximately $8,046,000 during the nine month periods ended December 31, 2007 and December 31, 2006, respectively.  The increase was primarily attributable to the litigation settlement of approximately $1,874,000 posted during the nine month period ended December 31, 2006 that related to the award from the Neurochem litigation.

 

Liquidity and Capital Resources

 

As of December 31, 2007, cash and cash equivalents were approximately $9,444,000.

 

We spent approximately $5,000 on equipment purchases during the three and nine month periods ended December 31, 2007.  We spent approximately $2,000 and $41,000, respectively, on equipment purchases during the three and nine month periods ended December 31, 2006.  No significant purchases of equipment are anticipated by us during the year ending March 31, 2008.

 

We periodically receive cash from the exercise of common stock options and warrants.  During the three month period ended December 31, 2007, we received approximately $187,000 from the exercise of warrants and approximately $2,000 from the exercise of options.  During the three month period ended December 31, 2006, we did not receive any funds for the exercise of warrants or options.

 

We believe our existing unrestricted cash and cash equivalents and the grants we have received or have been awarded and are awaiting disbursement of, will be sufficient to meet our planned expenditures through at least November 2008, although there can be no assurance we will not require additional funds.

 

Through December 31, 2007, we financed our operations with:

 

·	proceeds from various private placements of debt and equity securities, an initial public offering, and other cash contributed from stockholders, which in the aggregate raised approximately $77,608,000;

 

·	payments from research agreements, license agreements, foundation grants, and SBIR grants and STTR program grants of approximately $28,775,000; and

 

·	the use of stock, options and warrants in lieu of cash compensation.

 

Our cash resources have been used to finance, develop and begin commercialization of drug product candidates, including sponsored research, conduct of human clinical trials, capital expenditures, expenses associated with development of product candidates pursuant to an agreement, dated January 15, 1997, (the “Consortium Agreement”), among us and UNC-CH (to which each of Duke University, Auburn University and Georgia State University agreed shortly thereafter to become a party, and all of which, collectively with UNC-CH, are referred to as the “Consortium”) and, as contemplated by the Consortium Agreement, under a license agreement dated January 28, 2002 (“Consortium License Agreement”) with the Consortium, and general

 

-29-

---

 

and administrative expenses.  Over the next several years we expect to incur substantial additional research and development costs, including costs related to research in pre-clinical (laboratory) and human clinical trials, administrative expenses to support our research and development operations and marketing expenses to launch the sale of any commercialized product that may be developed.

 

Our future working capital requirements will depend upon numerous factors, including the progress of research, development and commercialization programs (which may vary as product candidates are added or abandoned), results of pre-clinical testing and human clinical trials, achievement of regulatory milestones, third party collaborators fulfilling their obligations to us, the timing and cost of seeking regulatory approvals, the level of resources that we devote to the engagement or development of manufacturing capabilities including the build-out of our subsidiary’s facility in China, our ability to maintain existing and to establish new collaborative arrangements with others to provide funding to support these activities, and other factors.  In any event, we will require substantial additional funds in addition to our existing resources to develop product candidates and to otherwise meet our business objectives.

 

Management’s plans for the remainder of the fiscal year, in addition to normal operations, include continuing their efforts to create joint ventures, obtain additional grants and to develop and enter into research, development and/or commercialization agreements with others.

 

                 Item 3.    Quantitative and Qualitative Disclosures about Market Risk.

 

The exposure of market risk associated with risk-sensitive instruments is not material, as our operations are conducted primarily in U.S. dollars and we invest primarily in short-term government obligations and other cash equivalents.  We intend to develop policies and procedures to manage market risk in the future if and when circumstances require.

 

                 Item 4.    Controls and Procedures.

 

Disclosures and Procedures

 

We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC.  Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining these procedures and, as required by the rules of the SEC, evaluate their effectiveness.  Based on their evaluation of our disclosure controls and procedures, which took place as of the end of the period covered by this Quarterly Report on Form 10-Q, our Chief Executive Officer and Chief Financial Officer believe that these procedures are effective to ensure that we are able to collect, process and disclose the information we are required to disclose in the reports we file with the SEC within the required time periods.

 

Internal Controls

 

We maintain a system of internal controls designed to provide reasonable assurance that: (1) transactions are executed in accordance with management’s general or specific authorization and (2) transactions are recorded as necessary to (a) permit preparation of financial statements in

 

-30-

---

 

conformity with generally accepted accounting principles and (b) maintain accountability for assets.  Access to assets is permitted only in accordance with management’s general or specific authorization and the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

Changes in Internal Controls

 

We have not made any changes in our internal control over financial reporting during the quarter ended December 31, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II.     OTHER INFORMATION

 

                Item 1.    Legal Proceedings. 

 

Gerhard Von der Ruhr et al. v. Immtech International, Inc. et. al.

 

In October 2003, Gerhard Von der Ruhr and his son Mark (the “Von der Ruhr Plaintiffs”) filed a complaint in the United States District Court for the Northern District of Illinois against the Company and certain officers and directors alleging breaches of a stock lock-up agreement, option agreements and a technology license agreement by the Company. The Von de Ruhr Plaintiffs also alleged a claim for intentional interference with contractual relations by certain officers of the Company.  The complaint sought unspecified monetary damages and punitive damages, in addition to equitable relief and costs.  In a filing made in late February 2005, the Von de Ruhr Plaintiffs specified damages of approximately $44.5 million in damages.

 

In 2005, one of the breach of contract claims was dismissed upon the Company’s motion for summary judgment.  On October 26, 2006, a preliminary pre-trial conference was held and the court granted the Company’s motions in limine to exclude plaintiffs’ damage claim for lost profits and prohibited plaintiff from offering expert testimony at trial on this issue.  The court subsequently granted a motion to sever the trial on Count V, regarding the technology license agreement, from the trial on the remaining counts.  The trial on the remaining counts concluded on December 7, 2007, and a jury returned a verdict against the Company and certain officers and directors for a total amount of $361,704.90. The Company immediately filed a motion with the court seeking to overturn the jury verdict, which the court subsequently denied. The Company is considering all options, including the filing of an appeal.

 

Item 1A.     Risk Factors.

 

In addition to those risk factors previously disclosed in Item 1A to Part I of our Form 10-K for the fiscal year ended March 31, 2007, we are now subject to the additional risk factor below.

 

The suspension of our clinical trials relating to pafuramidine may adversely affect our business, operations and stock price.

 

On December 20, 2007, the Food and Drug Administration (the “FDA”) informed us that it had placed all of our ongoing and projected clinical trials relating to the development of pafuramidine on clinical hold.  The FDA placed this clinical hold on the pafuramidine program after subjects in our Phase I safety study demonstrated abnormal liver function tests.  The

 

-31-

---

 

affected subjects do not currently have any signs and symptoms related to the liver abnormalities and our clinical follow-up of the subjects remains ongoing.

 

We have reviewed data from the Phase I safety study with experts in liver disease, our consortium scientific advisors and governance council, and the Data Safety Monitoring Board.  Such experts will assist us in preparing a report to be submitted to the FDA reviewing data related to the liver function of subjects from our prior and currently suspended pafuramidine trials. In addition, we are developing a risk management plan to monitor potential liver abnormalities in pafuramidine studies related to African sleeping sickness, PCP and malaria, which will be submitted to the FDA as a part of the report.

 

Any resumption of the clinical trials for the pafuramidine program will require regulatory approval from the FDA.  There can be no assurance that we will be able to resume these trials or that, if resumed, whether and when they will be completed.  In addition, we may need to modify the clinical trial protocol, which could require us to repeat a trial or conduct additional trials.  Accordingly, if we are unable to resume our trials relating to pafuramidine or if the trials are delayed or modified, our business, operations and stock price may be adversely affected.

 

                Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds. 

 

Recent Sales of Unregistered Securities.

 

All such shares of common stock herein described as issuances below were made pursuant to Section 4(2) of the Securities Act of 1933, as amended.

 

Option Exercise

 

On November 14, 2007, an executive officer exercised options to purchase 972 shares with an exercise price of $2.55 per share resulting in proceeds to the Company of approximately $2,479.

 

On December 17, 2007, options to purchase 7,000 shares with an exercise price of $2.55 per share were exercised on a cashless basis.  Common shares in the amount of 4,254 were issued.

 

Warrant Exercise

 

On October 5, 2007, an investor exercised warrants to purchase 20,000 shares with an exercise price of $6.125 per share resulting in proceeds to the Company of $122,500.

 

On November 14, 2007, an executive officer exercised warrants to purchase 10,000 shares with an exercise price of $6.47 per share resulting in proceeds to the Company of $64,700.

 

Conversion of Preferred Stock to Common Stock.

 

On November 27, 2007, a holder of Series B Convertible Preferred Stock, $0.01 par value (“Series B Stock”) converted 2,000 shares of Series B Preferred Stock into 12,574 shares of our common stock.

 

 

-32-

---

 

On November 27, 2007, holders of Series E Convertible Preferred Stock, $0.01 par value (“Series E Stock”) converted an aggregate of 8,000 shares of Series E Preferred Stock into an aggregate of 28,632 shares of our common stock.

 

Preferred Stock Dividend Payment.

 

On October 17, 2007, we issued 33,281 shares of common stock as payment of a dividend earned on outstanding preferred stock to the holders thereof: holders of Series A Stock earned 5,106 shares of common stock on 54,500 outstanding shares; holders of Series B Stock earned 1,682 shares of common stock on 13,464 outstanding shares; holders of Series C Stock earned 5,694 shares of common stock on 45,536 outstanding shares; holders of Series D Stock earned 10,804 shares of common stock on 115,200 outstanding shares; and holders of Series E Stock earned 9,995 shares of common stock on 106,600 outstanding shares.  We also paid holders of our outstanding preferred stock $507 in cash in lieu of fractional shares.

 

                Item 3.    Defaults Upon Senior Securities.

 

None

 

                Item 4.    Submission of Matters to a Vote of Security Holders.

 

Votes of the Stockholders

 

We held our Annual Meeting on November 29, 2007 at the Grand Hyatt in New York, NY.  The following matters were presented to our stockholders: (1) Proposal No. 1 – election of six directors to serve until the next annual meeting of the stockholders, (2) Proposal No. 2 – to approve the Immtech Pharmaceuticals, Inc. 2007 Stock Incentive Plan, and (3) Proposal No. 3 – ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2008.  The results of the votes are as follows:

 

Proposal 1 - Election of directors by the stockholders	Votes For	Authority Withheld
Eric L. Sorkin	11,725,099	891,981
Cecilia Chan	11,730,210	886,870
David Fleet	12,453,329	163,751
Judy Lau	11,650,918	966,162
Levi H. K. Lee, M.D.	11,740,152	876,928
Donald F. Sinex	12,369,464	247,616

 

 

-33-

---

 

	Votes For	Votes Against	Abstain *
Proposal 2 – Approve 2007 Stock Incentive Plan	3,673,624	1,711,553	172,789
Proposal 3 – Ratification of Deloitte & Touche as independent auditors	12,478,919	108,532	29,629

* Per the proxy statement, abstentions are considered votes against the proposal.

 

                Item 5.    Other Information.

 

None

 

                Item 6.    Exhibits.

 

Exhibit Number	Exhibit Description
3.1 (1)	Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2004
3.2 (2)	Certificate of Correction to Certificate of Incorporation dated December 14, 2005
3.3 (3)	Certificate of Amendment (Name Change) to Certificate of Incorporation dated March 22, 2006.
3.4 (4)	Amended and Restated Bylaws of the Company effective as of June 6, 2007
10.50*	Licensing Agreement, dated as of December 3, 2007, by and between Immtech Pharmaceuticals, Inc. and BioAlliance Pharma SA
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

*	Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.

 

(1)	Incorporated by Reference to our Form 10-K (File No. 001-14907), as filed with the Securities and Exchange Commission on June 14, 2004.

 

(2)	Incorporated by Reference to our Form 8-K (File No. 001-14907), as filed with the Securities and Exchange Commission on December 14, 2005.

 

(3)	Incorporated by Reference to our Form 8-K (File No. 001-14907), as filed with the Securities and Exchange Commission on March 23, 2006.

 

(4)	Incorporated by Reference to our Form 8-K (File No. 001-14907), as filed with the Securities Exchange Commission on June 12, 2007.

 

 

 

-34-

---

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	IMMTECH PHARMACEUTICALS, INC.
Date:  February 11, 2008	By:  /s/ Eric L. Sorkin                                                                          Eric L. Sorkin President and Chief Executive Officer
Date:  February 11, 2008	By:  /s/ Gary C. Parks                                                                          Gary C. Parks Treasurer, Secretary and Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 

---